These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31578241)

  • 1. Antibody-mediated targeting of TNFR2 activates CD8
    Tam EM; Fulton RB; Sampson JF; Muda M; Camblin A; Richards J; Koshkaryev A; Tang J; Kurella V; Jiao Y; Xu L; Zhang K; Kohli N; Luus L; Hutto E; Kumar S; Lulo J; Paragas V; Wong C; Suchy J; Grabow S; Dugast AS; Zhang H; Depis F; Feau S; Jakubowski A; Qiao W; Craig G; Razlog M; Qiu J; Zhou Y; Marks JD; Croft M; Drummond DC; Raue A
    Sci Transl Med; 2019 Oct; 11(512):. PubMed ID: 31578241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A TNFR2 antibody by countering immunosuppression cooperates with HMGN1 and R848 immune stimulants to inhibit murine colon cancer.
    Jiang M; Liu J; Yang D; Tross D; Li P; Chen F; Alam MM; Faustman DL; Oppenheim JJ; Chen X
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108345. PubMed ID: 34794079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
    Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
    J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Significance of Tumor Necrosis Factor Receptor Type II in CD8
    Ye LL; Wei XS; Zhang M; Niu YR; Zhou Q
    Front Immunol; 2018; 9():583. PubMed ID: 29623079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Necrosis Factor Receptor 2 Restricts the Pathogenicity of CD8(+) T Cells in Mice With Colitis.
    Punit S; Dubé PE; Liu CY; Girish N; Washington MK; Polk DB
    Gastroenterology; 2015 Oct; 149(4):993-1005.e2. PubMed ID: 26072395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer.
    Nie Y; He J; Shirota H; Trivett AL; Yang D; Klinman DM; Oppenheim JJ; Chen X
    Sci Signal; 2018 Jan; 11(511):. PubMed ID: 29295954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TNFR1 delivers pro-survival signals that are required for limiting TNFR2-dependent activation-induced cell death (AICD) in CD8+ T cells.
    Twu YC; Gold MR; Teh HS
    Eur J Immunol; 2011 Feb; 41(2):335-44. PubMed ID: 21268004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity.
    Chen Y; Jia M; Wang S; Xu S; He N
    Front Immunol; 2022; 13():835690. PubMed ID: 35251028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs.
    Torrey H; Butterworth J; Mera T; Okubo Y; Wang L; Baum D; Defusco A; Plager S; Warden S; Huang D; Vanamee E; Foster R; Faustman DL
    Sci Signal; 2017 Jan; 10(462):. PubMed ID: 28096513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer.
    Villarreal DO; L'Huillier A; Armington S; Mottershead C; Filippova EV; Coder BD; Petit RG; Princiotta MF
    Cancer Res; 2018 Sep; 78(18):5340-5348. PubMed ID: 30026324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells.
    Marriott JB; Clarke IA; Dredge K; Muller G; Stirling D; Dalgleish AG
    Clin Exp Immunol; 2002 Oct; 130(1):75-84. PubMed ID: 12296856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TNFR2-deficient memory CD8 T cells provide superior protection against tumor cell growth.
    Kim EY; Teh SJ; Yang J; Chow MT; Teh HS
    J Immunol; 2009 Nov; 183(10):6051-7. PubMed ID: 19841176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-125b-5p modulates the function of regulatory T cells in tumor microenvironment by targeting TNFR2.
    Jiang M; Yang Y; Niu L; Li P; Chen Y; Liao P; Wang Y; Zheng J; Chen F; He H; Li H; Chen X
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36319063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.
    Desbois M; Le Vu P; Coutzac C; Marcheteau E; Béal C; Terme M; Gey A; Morisseau S; Teppaz G; Boselli L; Jacques Y; Béchard D; Tartour E; Cassard L; Chaput N
    J Immunol; 2016 Jul; 197(1):168-78. PubMed ID: 27217584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents.
    Zou H; Li R; Hu H; Hu Y; Chen X
    Front Immunol; 2018; 9():594. PubMed ID: 29632537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated CD8+ T cells induce expansion of Vβ5+ regulatory T cells via TNFR2 signaling.
    Joedicke JJ; Myers L; Carmody AB; Messer RJ; Wajant H; Lang KS; Lang PA; Mak TW; Hasenkrug KJ; Dittmer U
    J Immunol; 2014 Sep; 193(6):2952-60. PubMed ID: 25098294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted killing of TNFR2-expressing tumor cells and T
    Torrey H; Khodadoust M; Tran L; Baum D; Defusco A; Kim YH; Faustman DL
    Leukemia; 2019 May; 33(5):1206-1218. PubMed ID: 30356161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation and characterization of novel co-stimulatory anti-mouse TNFR2 antibodies.
    Segués A; van Duijnhoven SMJ; Parade M; Driessen L; Vukovic N; Zaiss D; Sijts AJAM; Berraondo P; van Elsas A
    J Immunol Methods; 2021 Dec; 499():113173. PubMed ID: 34699840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4
    He T; Chen Y; Yang D; Islam MS; Chou CK; Liu J; Faustman DL; Oppenheim JJ; Chen X
    Cell Oncol (Dordr); 2023 Feb; 46(1):167-177. PubMed ID: 36369606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.
    Govindaraj C; Madondo M; Kong YY; Tan P; Wei A; Plebanski M
    Am J Hematol; 2014 Aug; 89(8):795-802. PubMed ID: 24757092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.